We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Flow-Through Testing Technology Expanded for HIV Diagnosis

By HospiMedica staff writers
Posted on 24 Dec 2007
A new range of rapid HIV testing products is being produced utilizing a new scientific test platform. More...


The core technology platform, which is the basis a new generation of infectious disease testing products, includes a rapid flow-through diagnostic device, assay, and multi-functional buffer.

The rapid diagnostic tests were developed by MedMira (Halifax, Canada) and are to be sold by the German company Vitest (Hennigsdorf, Germany). This is the first shipment of MedMira's private label product to a distributor in Europe. Under the private label agreement, Vitest will market and sell the new product under the Vitest brand and it will be a part of the Vitest suite of rapid testing products.

"Our rapid flow-through technology platform has an endless list of potential applications, for which our current product pipeline has barely scratched the surface,” said Hermes Chan, president and CEO of MedMira. "Our strategic goals involve the pursuit of a wide range of opportunities to diversify not only our own product portfolio, but also to make available a private label or OEM [original equipment manufacturer] capability to fill the needs of our partners. We are pleased to welcome Vitest as our first partner in this endeavor.”

MedMira is a developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics, and individuals worldwide with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal, MiraWell, MiraCare, and Multiplo brands. MedMira's rapid HIV test has achieved regulatory approvals in Canada, the United States, China, and the European Union.

The Maple Biosciences division of MedMira develops and commercializes diagnostic instruments based on two new biosensor-based technology platforms. Solutions developed by The Maple Biosciences division of MedMira enable routine laboratory tests to be performed in minutes, increasing laboratory automation, and streamlining the diagnosis of multiple conditions and diseases.


Related Links:
MedMira
Vitest

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.